

Novo Nordisk stripped comment

CSII for the treatment of diabetes (review) From:

Sent: 20 September 2007 11:41

To: Christopher Feinmann

Subject: CSII for the treatment of diabetes (review)

Attachments: Raslova_erratum.pdf; Raslova_Diab_Res_Clin_Pract_66_(2004)_193_201 - type 2.pdf

Dear Mr Feinmann

Thank you for the opportunity to review the assessment report for the continuous subcutaneous insulin infusion for the treatment of diabetes. Are comments are as follows:

a.. Whilst it is correct that the fast-acting insulin analogues currently available are aspart, lispro and glulisine, none of the studies referred to in this report involve glulisine. We therefore feel that it is inappropriate to include this insulin in the review of CSII therapy with analogue insulin.

b.. The report states that there is no evidence that MDI with analogue insulins is superior to that with human insulins in type 2 patients, based on the findings of the Cochrane review by Siebenhofer et al1. However, we would request that the Appraisal Committee also consider results of the study by Raslova et al2,3 (references attached). This study showed that basal-bolus therapy with insulin detemir and insulin aspart in type 2 patients gave comparable glycaemic control to NPH and human soluble insulin, but with significantly less nocturnal hypoglycaemia, less weight gain and lower day-to-day variation in fasting plasma glucose. This study was not included in the Cochrane review as it's duration was 22 weeks, with Siebenhofer et al only considering studies of 24 weeks or longer.

Kind regards

1. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews 2006 Issue 2 Chichester (UK): John Wiley & Sons Ltd, 2006

2. Raslova K, Bogoev M, Raz I, Leth G, Gall M-A, Hancu N. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Research and Clinical Practice 66, 2004, 193-201

3. Raslova K, Bogoev M, Raz I, Leth G, Gall M-A, Hancu N. Corrigendum to "Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes". Diabetes Research and Clinical Practice 72, 2006, 112

<<Raslova_erratum.pdf>> <<Raslova_Diab_Res_Clin_Pract_66_(2004)_193_201 - type 2.pdf>>

Novo Nordisk Ltd.
Broadfield Park
Brighton Road
Crawley
West Sussex RH11 9RT
United Kingdom
Registered Office : No. 1118740

A Changing Diabetes Bus World Tour
How can a bus help raise awareness about diabetes? Find out here

Novo Nordisk stripped comment

This e-mail (including any attachments) is intended for the addressee(s) stated above only and may contain confidential information protected by law. You are hereby notified that any unauthorized reading, disclosure, copying or distribution of this e-mail or use of information contained herein is strictly prohibited and may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete it immediately hereafter. Thank you.

Delivered via MessageLabs
